{"id":9131,"date":"2021-04-14T10:37:48","date_gmt":"2021-04-14T17:37:48","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9131"},"modified":"2021-04-15T10:38:31","modified_gmt":"2021-04-15T17:38:31","slug":"real-world-experience-of-bamlanivimab-for-covid-19-a-case-control-study","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/14\/real-world-experience-of-bamlanivimab-for-covid-19-a-case-control-study\/","title":{"rendered":"Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Adults with COVID-19 who were not hospitalized and received the monoclonal antibody therapy bamlanivimab (n = 218) had a 63% lower 30-day hospitalization rate than those who did not receive the treatment (n = 185) in a case-control study conducted between November 20, 2020 and January 19, 2021. Odds of hospitalization was 4.2 times higher among controls who had a referral order but did not receive bamlanivimab than those who received treatment. To prevent one hospitalization, 8 patients with mild or moderate COVID-19 would need to be treated with bamlanivimab.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Kumar et al.\u00a0(Apr 13, 2021). Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study. Clinical Infectious Diseases. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1093\/cid\/ciab305\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1093\/cid\/ciab305<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adults with COVID-19 who were not hospitalized and received the monoclonal antibody therapy bamlanivimab (n = 218) had a 63% lower 30-day hospitalization rate than those who did not receive the treatment (n = 185) in a case-control study conducted between November 20, 2020 and January 19, 2021. Odds of hospitalization was 4.2 times higher&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/14\/real-world-experience-of-bamlanivimab-for-covid-19-a-case-control-study\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-9131","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9131"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9131\/revisions"}],"predecessor-version":[{"id":9132,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9131\/revisions\/9132"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9131"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}